Hernigou Philippe, Merouse Guillaume, Duffiet Pascal, Chevalier Nathalie, Rouard Helene
Orthopaedic Surgery, Hospital Henri Mondor, Créteil, France,
Int Orthop. 2015 Jun;39(6):1219-25. doi: 10.1007/s00264-015-2724-8. Epub 2015 Mar 12.
While the use of bone marrow concentrate (BMC) has been described in the treatment of rotator cuff tears, the impact of a rotator cuff injury on the mesenchymal stem cells (MSCs) content present in the human shoulder has not been determined, especially with regard to changes in the levels of MSCs at the tendon-bone interface. With the hypothesis that there was a decreased level of MSCs at the tendon-bone interface tuberosity in patients with rotator cuff tear, we assessed the level of MSCs in the tuberosity of the shoulder of patients undergoing a rotator cuff repair.
We analysed the data of 125 patients with symptomatic rotator cuff tears and of 75 control patients without rotator cuff injury. We recorded the following data: size of tear, number of torn tendons, aetiology of the tear, lag time between onset of shoulder symptoms/injury and repair, and also fatty infiltration of muscles. Mesenchymal stem cell content at the tendon-bone interface tuberosity was evaluated by bone marrow aspiration collected in the humeral tuberosities of patients at the beginning of surgery.
A significant reduction in MSC content (from moderate, 30-50 %, to severe >70 %) at the tendon-bone interface tuberosity relative to the MSC content of the control was observed in all rotator cuff repair study patients. Severity of the decrease was statistically correlated to a number of factors, including the delay between onset of symptoms and surgery, number of involved tendons, fatty infiltration stage and increasing patient age.
This study demonstrates that the level of MSCs present in the greater tuberosity of patients with a rotator cuff tear decreases as a function of a number of clinical factors, including lag time from tear onset to treatment, tear size, number of tears and stage of fatty infiltration, among others. This information may help the practices in using biologic augmentation of a rotator cuff repair.
虽然骨髓浓缩物(BMC)已被用于治疗肩袖撕裂,但肩袖损伤对人肩部间充质干细胞(MSC)含量的影响尚未确定,尤其是肌腱-骨界面处MSC水平的变化。基于肩袖撕裂患者肌腱-骨界面结节处MSC水平降低的假设,我们评估了接受肩袖修复患者肩部结节处的MSC水平。
我们分析了125例有症状的肩袖撕裂患者和75例无肩袖损伤的对照患者的数据。我们记录了以下数据:撕裂大小、撕裂肌腱数量、撕裂病因、肩部症状/损伤发作与修复之间的延迟时间,以及肌肉的脂肪浸润情况。通过在手术开始时从患者肱骨结节处采集骨髓抽吸物来评估肌腱-骨界面结节处的间充质干细胞含量。
在所有肩袖修复研究患者中,观察到相对于对照组的MSC含量,肌腱-骨界面结节处的MSC含量显著降低(从中度,30%-50%,降至重度>70%)。降低的严重程度与多种因素在统计学上相关,包括症状发作与手术之间的延迟、受累肌腱数量、脂肪浸润阶段和患者年龄增加。
本研究表明,肩袖撕裂患者大结节处的MSC水平会随着一些临床因素而降低,这些因素包括从撕裂发作到治疗的延迟时间、撕裂大小、撕裂数量和脂肪浸润阶段等。这些信息可能有助于在肩袖修复中使用生物增强技术的实践。